This study is looking at whether a single dose of Vitamin A can help reduce a common complication called chronic graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. GVHD happens when the new immune cells from the donor attack the patient's body. Researchers believe that Vitamin A, which helps with gut health, might lower the risk of this problem. You might be able to join if you are 18 or older, are scheduled for an allogeneic stem cell transplant, and have low vitamin A levels. The study will compare patients who receive Vitamin A to those who receive a placebo (an inactive pill). The main goal is to see if Vitamin A reduces moderate-to-severe chronic GVHD one year after your transplant. The current recruitment status is unclear.

Study design

This is a randomized, double-blinded study comparing Vitamin A to a placebo, with a planned enrollment of 190 participants.

What's involved

Enrolled subjects will receive one observed oral Vitamin A dose, prior to their hematopoietic stem cell transplant (HSCT), in the outpatient clinic or inpatient Bone Marrow Transplant (BMT) floor.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, incidence of moderate-severe chronic graft versus host disease (GVHD), is measured at 1 year after transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.